SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 167
EU - Europa 106
AS - Asia 21
SA - Sud America 1
Totale 295
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 167
IT - Italia 44
GB - Regno Unito 42
HK - Hong Kong 10
FI - Finlandia 7
CN - Cina 5
DE - Germania 3
RU - Federazione Russa 3
TR - Turchia 3
CH - Svizzera 2
JP - Giappone 2
PL - Polonia 2
BR - Brasile 1
CZ - Repubblica Ceca 1
LB - Libano 1
MK - Macedonia 1
UA - Ucraina 1
Totale 295
Salva come PNG Salva come JPEG
Città #
Chandler 39
Ferrara di Monte Baldo 18
London 16
Hong Kong 10
Bologna 7
Hounslow 6
Princeton 5
Ashburn 4
Chiswick 4
Ferrara 4
Helsinki 4
Chicago 3
Lappeenranta 3
Southwark 3
Beijing 2
Frankfurt Am Main 2
Gdansk 2
Islington 2
Monza 2
Nakanishi 2
Sciacca 2
Shanghai 2
Sivas 2
Wandsworth 2
Americana 1
Arezzo 1
Bremen 1
Florence 1
Kilburn 1
Los Angeles 1
Milan 1
New Bedfont 1
New Jersey 1
Plaistow 1
Prilep 1
Rome 1
Saint Petersburg 1
Trenton 1
Verona 1
Washington 1
Totale 162
Salva come PNG Salva come JPEG
Nome #
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 27
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 17
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 15
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 13
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 12
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 10
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 10
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 10
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 8
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 8
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 8
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 8
COVID and Lung Cancer 8
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 7
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 7
The emerging role of cancer nanotechnology in the panorama of sarcoma 7
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 6
Circulating haemopoietic and endothelial cells are decreased in COPD 6
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 6
Recombinant transmembrane CD59 (CD59-TM) confers complement resistence to GPI-anchored protein detective melanoma cells. 6
Challenges in lung cancer therapy during the COVID-19 pandemic 6
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 6
Biomarkers for immune checkpoint inhibitors--authors' reply 6
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 6
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 6
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 5
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 5
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 5
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 5
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 5
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 5
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 5
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 5
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 5
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 5
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 4
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 4
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 4
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 4
The future of mesothelioma treatment: time to shift gear 4
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 3
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 3
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 3
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 3
Epigenetic immunomodulation of hematopoietic malignancies 3
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 3
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 3
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 3
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 3
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 3
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 3
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 3
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 2
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 2
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 2
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 2
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 2
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 2
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 2
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 2
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 1
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 1
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 1
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 1
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 1
Immune checkpoint blockade in malignant mesothelioma 1
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 1
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 1
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 1
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 1
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 1
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 1
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 1
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 1
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 1
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 1
Totale 367
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 57
Totale 18.474
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024165 10 47 21 13 19 4 4 15 9 13 10 0
Totale 367